Skip to main content
GutCited

Berberine per Gut Dysbiosis

D

Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dgut\u002Ddysbiosis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

D

In sintesi

Preclinical evidence that berberine modulates microbiome composition. Limited human microbiome data.

Key Study Findings

Other
Design and Activity Evaluation of Berberine-Loaded Dual pH and Enzyme-Sensitive Colon-Targeting Microparticles.
Dose: None vs: Free berberine; DSS-induced UC model vs normal mice Outcome: DAI scores, inflammatory cytokines, gut microbiota Effetto: None <0.01 (DAI); <0.05 (cytokines)

Popolazione: DSS-induced UC mouse model (male KM mice)

Other
Oxyberberine alleviates fructose-induced hyperuricemia by modulating purine metabolism and gut microbiota.
Dose: None vs: Fructose-induced HUA control Outcome: Serum uric acid levels Effetto: None None

Popolazione: Fructose-induced hyperuricemia rats

Review
Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

Other
Co-administration of berberine and evodiamine: Mitigating evodiamine-induced hepatotoxicity and potentiating colitis treatment.
Dose: None vs: EVO alone; colitis mouse model Outcome: Hepatotoxicity markers and colitis inflammation Effetto: None None

Popolazione: C57 mice (normal and colitis models)

In Vitro 1 weeks
Phellodendron bark extract and berberine chloride suppress microbiome dysbiosis in a saliva-derived in vitro microcosm …
Dose: None vs: Untreated biofilm control Outcome: Microbiome dysbiosis suppression in biofilm Effetto: None None

Popolazione: Saliva-derived in vitro microcosm biofilm model with P. gingivalis

Key Statistics

2

Studi

100

Partecipanti

Positive

D

Grado

Referenced Papers

Inflammatory bowel diseases 2025 2 citazioni
Gut microbes 2023 108 citazioni
Comprehensive Physiology 2021 21 citazioni
Biomedicine & pharmacotherapy … 2019 72 citazioni
Alternative therapies in … 2017 9 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
500-1,500 mg/day in divided doses
siboprotocol:
500 mg two to three times daily for 4 weeks (as part of herbal antimicrobial protocol)
giantimicrobial:
500 mg twice daily

Limite massimo: Generally well-tolerated up to 1,500 mg/day in divided doses

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --
None 1 weeks Positive --
None -- Mixed --
None -- Positive --

Momento migliore per l'assunzione: With meals; divide doses throughout the day (do not take full daily dose at once)

Safety & Side Effects

Effetti collaterali segnalati

  • GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common
  • May cause uterine contractions (contraindicated in pregnancy)
  • Headache
  • Skin rash (rare)

Interazioni note

  • Diabetes medications (berberine significantly lowers blood sugar; risk of hypoglycemia)
  • Cyclosporine (berberine inhibits CYP3A4, increasing cyclosporine levels)
  • Anticoagulants (may have additive blood-thinning effects)
  • Metformin (additive glucose-lowering effect; monitor closely)
  • Macrolide antibiotics (berberine inhibits CYP3A4)

Livello di assunzione massimo tollerabile: Generally well-tolerated up to 1,500 mg/day in divided doses

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Berberine help with Gut Dysbiosis?
Based on 2 studies with 100 participants, there is preliminary evidence that needs more research that Berberine may support Gut Dysbiosis management. Our evidence grade is D (Very Early Research).
How much Berberine should I take for Gut Dysbiosis?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include GI side effects (diarrhea, constipation, flatulence, abdominal pain) — most common, May cause uterine contractions (contraindicated in pregnancy), Headache, Skin rash (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and Gut Dysbiosis?
We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 100 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.